Issuu on Google+

Innovation through Clustering with regard to Biotechnology and Life Science Igor Fisch, PhD Chairman and CEO, Selexis SA

© Igor Fisch 2013 All Rights Reserved.

© Copyright 2013 Selexis SA. All rights reserve 1


Agenda 1. Innovation in Switzerland: How to stimulate innovation and bring it to the market: the example of Venture Kick initiative 2. Clustering in Biotech: Is this a necessity? One example of bio-incubators in Geneva 3. Private experience starting and running businesses  Selexis SA  BioXpress Therapeutics SA  Viroblock SA  Stemergie Biotechnology SA  Affitech A/S 4. Discussions

© Igor Fisch 2013 All Rights Reserved.

2


Innovation in Switzerland

Switzerland has a leading role in innovation and competitiveness 1. 2. 3. 4.

ICT Electronics/Mechanics Medtech Lifescience (Biotech)

Š Igor Fisch 2013 All Rights Reserved.

5. 6. 7. 8.

Cleantech Micro-/Nanotechnology Materials/Chemicals Others 3


Venture Kick: Stimulation of Entrepreneurship

Philanthropic initiative launched by Swiss Foundations

     

Gebert Rüf Foundation Ernst Göhner Foundation Avina Foundation OPO Foundation Lombard Odier Foundation DebioPharm group

Pre-seed fund aiming at promoting and speeding-up new start-ups in the overall high-tech environment in Switzerland  Double the number of spin-offs In the midterm we want to double the number of spin-off projects from Swiss Universities.  Cut time-to-market by half We want to significantly speed up the process of structuring business opportunities and startup companies.  Improve the quality of spin-off projects We want to substantially improve the quality of projects in terms of Executed VC and Business Angel-Investments. © Igor Fisch 2013 All Rights Reserved.

4


Venture Kick: How Does it Work? A strong governance geared towards results

Strategic Board Dr. Pascale Vonmont GEBERT RÜF STIFTUNG

Dr. Roger Schmid ERNST GÖHNER STIFTUNG

Dr. Igor Fisch SELEXIS SA

Management Team Jordi Montserrat Co-managing director

© Igor Fisch 2013 All Rights Reserved.

Beat Schillig Co-managing director

5


Venture Kick: The Process

Š Igor Fisch 2013 All Rights Reserved.

6


Venture Kick: The Results (2007-2013)  Over 1’200 applications since September 2007  Over 600 candidates presented  302 projects received 11’020’000 CHF  Over 210 startup companies incorporated (180 still active)

 57 venture kickers made it to the TOP 100 SWISS STARTUPS  Over 2’000 new jobs created (FTEs)  365’000’000 CHF in financing raised by the venture kickers

© Igor Fisch 2013 All Rights Reserved.

7


Is Clustering a Necessity?

Š Igor Fisch 2013 All Rights Reserved.

8


The Clustering Effect: e.g. FONGIT Incubator La Fondation Genevoise pour l’Innovation Technologique (FONGIT) Mission

Facilitate innovation and economic value creation

Incubator

Founding, hosting & growing HighTech start-ups

Industries

CleanTech, ICT, IT, medTech, nanotech

Collaborations CTI, and financing oganisations Offices

hosting 20+ tech companies in 3000 m2 furnished space

Services

administration, accounting, financial, company foundation

Team

4 experimented coaches

Financing

Fongit Seed Invest- up to 500 k CHF per company

Š Igor Fisch 2013 All Rights Reserved.

9


The Clustering Effect: e.g. FONGIT Incubator

Incubator in Geneva grouping > 30 companies  Help in Start-up phase  Selexis SA (since 2001)  Viroblock SA (since 2005)  BioXpress Therapeutics SA (since 2010)

 Help growing and managing company  Stemergie Biotechnology SA (since 2012)  Affitech A/S (2010-2012)

© Igor Fisch 2013 All Rights Reserved.

10


The Clustering Effect: my Experience 1/4

Since 2001  Biotech comp. developing production tools for the industry  Impact on COGS for manufacturing recombinant protein drugs (EPO, Mabs)

 Break-even in 2005  18 FTEs  Patent portfolio: 137 granted, 30 pending and 3 provisional

 > 40 products in clinical trials, manufactured with Selexis’ technologies © Igor Fisch 2013 All Rights Reserved.

11


The Clustering Effect: my Experience 2/4

Since 2005  Biotech company developing products to fight pathogenic viral infections  Product efficient against all types of enveloped viruses (e.g. influenza, HIV,…)  Product positioned to deliver topical anti-viral products (such as masks)

© Igor Fisch 2013 All Rights Reserved.

12


The Clustering Effect: my Experience 3/4

Since 2005  Philosophy: all patients should have access to safe and high-quality biologic

therapeutics at affordable costs.  Products: high-quality biosimilar biologic APIs for unmet need indications such as cancer, inflammation and autoimmunity

 Mission: Cost-competitive biosimilar biologic API (MAb and MAb-like biosimilar drugs) to the highest EMA safety and quality standards.

© Igor Fisch 2013 All Rights Reserved.

13


The Clustering Effect: my Experience 4/4

Š Igor Fisch 2013 All Rights Reserved.

14


Discussions

Š Igor Fisch 2013 All Rights Reserved.

15


Dr. Igor Fisch